Acinetobacter Pneumonia Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Xacduro, Polymyxins, Cephalosporins, Carbapenems), By Route Of Administration (Oral, Parenteral), By Region, And Segment Forecasts, 2024 - 2030
Acinetobacter Pneumonia Therapeutics Market Growth & Trends
The global acinetobacter pneumonia therapeutics market size is expected to reach USD 470.96 million by 2030, registering a CAGR of 6.70% from 2024 to 2030, according to a new report by Grand View Research, Inc. Several factors are responsible for driving market growth including a high incidence of acinetobacter infections, rising antibiotic resistance, extensive R&D, and favorable government initiatives & funding, and rising drug resistance. Acinetobacter baumannii is a major pathogen responsible for causing hospital-acquired infections in hospitalized patients. The pathogen causes ventilator-associated pneumonia and bloodstream infection. This strain of microorganisms has been reported to be multidrug-resistant and can spread extremely fast.
The treatment of this microorganism can be challenging and is hampered due to the multidrug resistance of the Acinetobacter baumannii. Combination therapy is the most widely used treatment for these kinds of infections. The first line of treatment for acinetobacter pneumonia includes drug classes, such as β-lactam antibiotics, cephalosporins, carbapenem, fluoroquinolone, sulbactam, and sulfonamide. The therapeutics are used in monotherapy or as part of combination therapy depending on the severity of illness. In case the first-line treatment is not effective, second-line antibiotics are administered, which include drug classes, such as aminoglycoside, polymyxins, tetracycline, and glycylcycline. These drugs are considered second-line due to their adverse effects.
Acinetobacter Pneumonia Therapeutics Market Report Highlights
- The cephalosporins drug class segment accounted for the largest revenue share in 2023. Ceftazidime is used as a first-line treatment; cefiderocol is used as second-linene treatment for the disease
- In addition, the newly launched Xacduro under the sulbactam segment is expected to grow at a significant CAGR during the forecast period
- Based on the route of administration, the parenteral segment accounted for the largest revenue share in 2023. The rapid and direct delivery of antibiotics via the IV route ensures rapid absorption and efficacy and makes it the preferred method for treating severe infections
- Xacduro (sulbactam for injection; durlobactam for injection), polymyxins (colistin), carbapenems, and aminoglycosides are some of the drugs administered parenterally for the treatment of acinetobacter pneumonia
- In 2023, North America dominated with a share of 37.31% owing to the advanced healthcare infrastructure, high awareness levels, and extensive research activities for clinical trials
- The region has a high prevalence of acinetobacter pneumonia along with high awareness about disease diagnosis and treatment
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Drug Class
- 1.2.2. Route of Administration
- 1.3. Regional scope
- 1.4. Estimates and forecasts timeline
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased database
- 1.6.2. GVR’s internal database
- 1.6.3. Secondary sources
- 1.6.4. Primary research
- 1.6.5. Details of primary research
- 1.6.5.1. Data for primary interviews in North America
- 1.6.5.2. Data for primary interviews in Europe
- 1.6.5.3. Data for primary interviews in Asia Pacific
- 1.6.5.4. Data for primary interviews in Latin America
- 1.6.5.5. Data for Primary interviews in MEA
- 1.7. Information or Data Analysis
- 1.7.1. Data analysis models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity flow analysis (Model 1)
- 1.9.2. Approach 1: Commodity flow approach
- 1.9.3. Volume price analysis (Model 2)
- 1.9.4. Approach 2: Volume price analysis
- 1.10. List of Secondary Sources
- 1.11. List of Primary Sources
- 1.12. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Drug class outlook
- 2.2.2. Route of administration outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Acinetobacter Pneumonia Therapeutics Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increasing incidence of Acinetobacter infections
- 3.2.1.2. Increasing prevalence of antibiotic resistance
- 3.2.1.3. Increasing research & development and fundings
- 3.2.2. Market restraint analysis
- 3.2.2.1. Side effects and adverse reactions
- 3.2.2.2. High cost of drug development
- 3.3. Acinetobacter Pneumonia Therapeutics Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.3. Pricing Analysis
- 3.3.4. Pipeline Analysis
- Chapter 4. Acinetobacter Pneumonia Therapeutics Market: Drug Class Estimates & Trend Analysis
- 4.1. Global Acinetobacter Pneumonia Therapeutics Market: Drug Class Segment Dashboard
- 4.2. Global Acinetobacter Pneumonia Therapeutics Market: Drug Class Movement Analysis
- 4.3. Global Acinetobacter Pneumonia Therapeutics Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
- 4.4. Cephalosporins
- 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. Fluoroquinolone
- 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.6. Glycylcycline
- 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.7. Carbapenem
- 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.8. β-Lactam antibiotics
- 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.9. Sulbactam
- 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.10. Aminoglycoside
- 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.11. Polymyxins
- 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.12. Tetracycline
- 4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.13. Sulfonamide
- 4.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.14. Other
- 4.14.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 5. Acinetobacter Pneumonia Therapeutics Market: Route of Administration Estimates & Trend Analysis
- 5.1. Global Acinetobacter Pneumonia Therapeutics Market: Route of Administration Segment Dashboard
- 5.2. Global Acinetobacter Pneumonia Therapeutics Market: Route of Administration Movement Analysis
- 5.3. Global Acinetobacter Pneumonia Therapeutics Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
- 5.4. Parenteral
- 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5. Oral
- 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Other
- 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 6. Acinetobacter Pneumonia Therapeutics Market: Regional Estimates & Trend Analysis by
- 6.1. Regional Market Dashboard
- 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 6.3. North America
- 6.3.1. U.S.
- 6.3.1.1. Key country dynamics
- 6.3.1.2. Regulatory framework/ reimbursement structure
- 6.3.1.3. Competitive scenario
- 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.2. Canada
- 6.3.2.1. Key country dynamics
- 6.3.2.2. Regulatory framework/ reimbursement structure
- 6.3.2.3. Competitive scenario
- 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4. Europe
- 6.4.1. UK
- 6.4.1.1. Key country dynamics
- 6.4.1.2. Regulatory framework/ reimbursement structure
- 6.4.1.3. Competitive scenario
- 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.2. Germany
- 6.4.2.1. Key country dynamics
- 6.4.2.2. Regulatory framework/ reimbursement structure
- 6.4.2.3. Competitive scenario
- 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.3. France
- 6.4.3.1. Key country dynamics
- 6.4.3.2. Regulatory framework/ reimbursement structure
- 6.4.3.3. Competitive scenario
- 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.4. Italy
- 6.4.4.1. Key country dynamics
- 6.4.4.2. Regulatory framework/ reimbursement structure
- 6.4.4.3. Competitive scenario
- 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.5. Spain
- 6.4.5.1. Key country dynamics
- 6.4.5.2. Regulatory framework/ reimbursement structure
- 6.4.5.3. Competitive scenario
- 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.6. Norway
- 6.4.6.1. Key country dynamics
- 6.4.6.2. Regulatory framework/ reimbursement structure
- 6.4.6.3. Competitive scenario
- 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.7. Sweden
- 6.4.7.1. Key country dynamics
- 6.4.7.2. Regulatory framework/ reimbursement structure
- 6.4.7.3. Competitive scenario
- 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.8. Denmark
- 6.4.8.1. Key country dynamics
- 6.4.8.2. Regulatory framework/ reimbursement structure
- 6.4.8.3. Competitive scenario
- 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Asia Pacific
- 6.5.1. Japan
- 6.5.1.1. Key country dynamics
- 6.5.1.2. Regulatory framework/ reimbursement structure
- 6.5.1.3. Competitive scenario
- 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.2. China
- 6.5.2.1. Key country dynamics
- 6.5.2.2. Regulatory framework/ reimbursement structure
- 6.5.2.3. Competitive scenario
- 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.3. India
- 6.5.3.1. Key country dynamics
- 6.5.3.2. Regulatory framework/ reimbursement structure
- 6.5.3.3. Competitive scenario
- 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.4. Australia
- 6.5.4.1. Key country dynamics
- 6.5.4.2. Regulatory framework/ reimbursement structure
- 6.5.4.3. Competitive scenario
- 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.5. South Korea
- 6.5.5.1. Key country dynamics
- 6.5.5.2. Regulatory framework/ reimbursement structure
- 6.5.5.3. Competitive scenario
- 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.6. Thailand
- 6.5.6.1. Key country dynamics
- 6.5.6.2. Regulatory framework/ reimbursement structure
- 6.5.6.3. Competitive scenario
- 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. Latin America
- 6.6.1. Brazil
- 6.6.1.1. Key country dynamics
- 6.6.1.2. Regulatory framework/ reimbursement structure
- 6.6.1.3. Competitive scenario
- 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.2. Mexico
- 6.6.2.1. Key country dynamics
- 6.6.2.2. Regulatory framework/ reimbursement structure
- 6.6.2.3. Competitive scenario
- 6.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.3. Argentina
- 6.6.3.1. Key country dynamics
- 6.6.3.2. Regulatory framework/ reimbursement structure
- 6.6.3.3. Competitive scenario
- 6.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7. MEA
- 6.7.1. South Africa
- 6.7.1.1. Key country dynamics
- 6.7.1.2. Regulatory framework/ reimbursement structure
- 6.7.1.3. Competitive scenario
- 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.2. Saudi Arabia
- 6.7.2.1. Key country dynamics
- 6.7.2.2. Regulatory framework/ reimbursement structure
- 6.7.2.3. Competitive scenario
- 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.3. UAE
- 6.7.3.1. Key country dynamics
- 6.7.3.2. Regulatory framework/ reimbursement structure
- 6.7.3.3. Competitive scenario
- 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.4. Kuwait
- 6.7.4.1. Key country dynamics
- 6.7.4.2. Regulatory framework/ reimbursement structure
- 6.7.4.3. Competitive scenario
- 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Company/Competition Categorization
- 7.3. Vendor Landscape
- 7.3.1. List of key distributors and channel partners
- 7.3.2. Key customers
- 7.3.3. Key company market share analysis, 2023
- 7.3.4. Pfizer Inc.
- 7.3.4.1. Company overview
- 7.3.4.2. Financial performance
- 7.3.4.3. Product benchmarking
- 7.3.4.4. Strategic initiatives
- 7.3.5. Merck & Co., Inc.
- 7.3.5.1. Company overview
- 7.3.5.2. Financial performance
- 7.3.5.3. Product benchmarking
- 7.3.5.4. Strategic initiatives
- 7.3.6. GlaxoSmithKline plc (GSK)
- 7.3.6.1. Company overview
- 7.3.6.2. Financial performance
- 7.3.6.3. Product benchmarking
- 7.3.6.4. Strategic initiatives
- 7.3.7. AstraZeneca plc
- 7.3.7.1. Company overview
- 7.3.7.2. Financial performance
- 7.3.7.3. Product benchmarking
- 7.3.7.4. Strategic initiatives
- 7.3.8. Novartis AG
- 7.3.8.1. Company overview
- 7.3.8.2. Financial performance
- 7.3.8.3. Product benchmarking
- 7.3.8.4. Strategic initiatives
- 7.3.9. Johnson & Johnson
- 7.3.9.1. Company overview
- 7.3.9.2. Financial performance
- 7.3.9.3. Product benchmarking
- 7.3.9.4. Strategic initiatives
- 7.3.10. Sanofi S.A.
- 7.3.10.1. Company overview
- 7.3.10.2. Financial performance
- 7.3.10.3. Product benchmarking
- 7.3.10.4. Strategic initiatives
- 7.3.11. Bayer AG
- 7.3.11.1. Company overview
- 7.3.11.2. Financial performance
- 7.3.11.3. Product benchmarking
- 7.3.11.4. Strategic initiatives
- 7.3.12. Basilea Pharmaceutica
- 7.3.12.1. Company overview
- 7.3.12.2. Financial performance
- 7.3.12.3. Product benchmarking
- 7.3.12.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook